Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05210374 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory Sarcomas

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated August 6, 2026 (before its estimated September 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. 2 versions Re-verified since Jun 4, 2026, no change to tracked fieldsv10-v11
  2. Primary completion date: Apr 1, 2026 to Sep 1, 2026v9
  3. Primary completion date: Apr 1, 2025 to Apr 1, 2026
    • Study completion date: Apr 1, 2025 to Dec 31, 2026
    v8
  4. Primary completion date: Oct 1, 2024 to Apr 1, 2025
    • Study completion date: Nov 1, 2024 to Apr 1, 2025
    v7
  5. Primary completion date: Apr 1, 2024 to Oct 1, 2024
    • Study completion date: May 1, 2024 to Nov 1, 2024
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Start date: Jan 24, 2023 to Mar 9, 2023
    • Primary completion date: Oct 2023 to Apr 1, 2024
    • Study completion date: Nov 2023 to May 1, 2024
    v5
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 2022 to Jan 24, 2023
    • Site details revised
    v4
  3. Start date: Sep 2022 to Dec 2022v3
  4. Start date: Mar 2022 to Sep 2022v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to test the safety of combining the disulfiram (DSF) and copper gluconate (Cu) to liposomal doxorubicin to treat patients with sarcomas that recurred or did not respond to initial treatment.
Trial Details
NCT Number NCT05210374
Lead Sponsor Case Comprehensive Cancer Center
Conditions
(from sponsor)		 Relapsed Sarcomas
Related terms Osteosarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov